1. Home
  2. KALA vs NVNI Comparison

KALA vs NVNI Comparison

Compare KALA & NVNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • NVNI
  • Stock Information
  • Founded
  • KALA 2009
  • NVNI 2019
  • Country
  • KALA United States
  • NVNI Brazil
  • Employees
  • KALA N/A
  • NVNI N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • NVNI
  • Sector
  • KALA Health Care
  • NVNI
  • Exchange
  • KALA Nasdaq
  • NVNI Nasdaq
  • Market Cap
  • KALA 26.2M
  • NVNI 31.5M
  • IPO Year
  • KALA 2017
  • NVNI N/A
  • Fundamental
  • Price
  • KALA $7.38
  • NVNI $0.54
  • Analyst Decision
  • KALA Strong Buy
  • NVNI
  • Analyst Count
  • KALA 3
  • NVNI 0
  • Target Price
  • KALA $14.00
  • NVNI N/A
  • AVG Volume (30 Days)
  • KALA 204.0K
  • NVNI 11.7M
  • Earning Date
  • KALA 08-05-2025
  • NVNI 08-12-2025
  • Dividend Yield
  • KALA N/A
  • NVNI N/A
  • EPS Growth
  • KALA N/A
  • NVNI N/A
  • EPS
  • KALA N/A
  • NVNI N/A
  • Revenue
  • KALA N/A
  • NVNI $31,250,627.00
  • Revenue This Year
  • KALA N/A
  • NVNI $12.05
  • Revenue Next Year
  • KALA N/A
  • NVNI $15.02
  • P/E Ratio
  • KALA N/A
  • NVNI N/A
  • Revenue Growth
  • KALA N/A
  • NVNI 1491.58
  • 52 Week Low
  • KALA $2.92
  • NVNI $0.14
  • 52 Week High
  • KALA $11.20
  • NVNI $12.19
  • Technical
  • Relative Strength Index (RSI)
  • KALA 74.24
  • NVNI 75.33
  • Support Level
  • KALA $5.35
  • NVNI $0.35
  • Resistance Level
  • KALA $8.49
  • NVNI $0.44
  • Average True Range (ATR)
  • KALA 0.79
  • NVNI 0.07
  • MACD
  • KALA 0.24
  • NVNI 0.03
  • Stochastic Oscillator
  • KALA 97.13
  • NVNI 64.12

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

Share on Social Networks: